DrugPatentWatch Database Preview

Details for Patent: 7,304,078

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,304,078 protect, and when does it expire?

Patent 7,304,078 protects ZONTIVITY and is included in one NDA.

This patent has one hundred and sixty-three patent family members in thirty-seven countries.

Summary for Patent: 7,304,078

Title:	Thrombin receptor antagonists
Abstract:	Heterocyclic-substituted tricyclics of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein: the dotted line represents an optional single bond; represents an optional double bond; n is 0 2; Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14; R.sup.13 and R.sup.14 are independently selected from (C.sub.1 C.sub.6)alkyl, (C.sub.3 C.sub.8)cycloalkyl, --OH, (C.sub.1 C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1 C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3 6 atoms; Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Inventor(s):	Chackalamannil; Samuel (Califon, NJ), Greenlee; William J. (Teaneck, NJ), Wang; Yuguang (North Brunswick, NJ), Wu; Wenxue (Princeton Junction, NJ), Veltri; Enrico P. (Princeton, NJ), Xia; Yan (Edison, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	10/412,982
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,304,078

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Xspire Pharma	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014		RX	Yes	Yes			Y	Y		REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

International Family Members for US Patent 7,304,078

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	028952
Argentina	039570
Argentina	045809
Argentina	047088
Argentina	098260